Document is current

Article History

Received: 29 May 2023

Accepted: 15 October 2023

First Online: 30 October 2023

Declarations

:

: All authors (J.H. Jang, S.H. Jeong, and Y.B. Lee) have no conflicts of interest to disclose.

: Clinical studies were conducted in accordance with the Rules of Good Clinical Practice and the revised Declaration of Helsinki for Biomedical Research with Human Subjects. All subjects were physically normal and had no prior history of hypersensitivity or related reactions to steroid drugs. In addition, healthy adults aged 19–55 years had no history of digestive, liver, kidney, cardiovascular, central nervous system, endocrine, or blood diseases in the past and had not been taking any other drugs. All subjects underwent a physical examination, clinical screening, complete blood count, urinalysis, and blood chemistry analysis prior to participation in this clinical study to confirm their physical health.

: All subjects provided written informed consent prior to their participation in bioequivalence and pharmacokinetic studies.

: All data were anonymized, and participants were informed that the results of this study may be subject to publication and presentation in meetings.

: The clinical study protocol used in this study was thoroughly reviewed and approved by the Institutional Review Board of the Institute of Bioequivalence and Bridging Study, Chonnam National University, Gwangju, Republic of Korea. The bioequivalence study permit numbers are as follows: 051114; 08.08.2005.